Project Grant R43AI192175
Award Date 9/9/25
Completion Date 8/31/27
Dollars Obligated $300K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Missouri, USA
Similar Awards
- This federal Project Grant award of $300,001 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research by Fimbrion Therapeutics Inc. to develop novel small molecule drugs targeting the respiratory protein QcrB in mycobacteria. The goal is to create new antimicrobial therapies to treat infections caused by non-tuberculous mycobacteria (NTM), which are highly resistant to existing antibiotics...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $298,829 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Tarn Biosciences, Inc. to develop novel nitroreductase-activated inhibitor compounds as treatments for tuberculosis (TB) and nontuberculous mycobacterial (NTM) infections. The funding, awarded on August 21, 2025, supports the discovery and preclinical development of a lead candidate compound, HC2210, which has shown...
- This Project Grant award of $423,500 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to determine the potential of phenylalanine (Phe) biosynthesis as a novel drug target for treating tuberculosis caused by Mycobacterium tuberculosis (MTB). The award will enable the development of MTB strains that conditionally express enzymes in the Phe biosynthesis pathway, which will be used to...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2,248,740 Project Grant through the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to Michigan State University on July 7, 2025. The grant supports the development of a new series of nitrofuran compounds that are potent inhibitors against Mycobacterium tuberculosis (MTB) and Mycobacterium abscessus (MAB), the bacteria that cause tuberculosis and non-tuberculous mycobacterial infections,...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $721,194 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Florida State University (FSU) to conduct research on membrane protein complexes involved in the cell division process of Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis (TB). The 5-year project, beginning March 1, 2025, aims to structurally characterize the FtsQ-FtsZ and FtsQ-FtsB-FtsL protein...
- This Project Grant award of $300,000 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research by Fimbrion Therapeutics Inc. to develop small molecule glycoside inhibitors targeting the LecB lectin protein in Pseudomonas aeruginosa (PA) bacteria. The goal is to create novel therapeutics to disrupt PA biofilm formation and enhance the efficacy of antibiotics in treating PA infections,...
- This Project Grant award of $265,650 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to develop novel medicinal chemistry strategies to overcome multidrug-resistant tuberculosis (MDR-TB) and rifampicin-resistant TB (RR-TB). The research aims to establish the structure-activity relationship and mechanism of action of modified rifabutin analogs that demonstrate enhanced potency against...
- The federal Project Grant award of $746,602 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Cornell University. The objective of this 5-year project is to examine how compounds that stimulate cyclic AMP (cAMP) production in the tuberculosis (TB) bacterium Mycobacterium tuberculosis (MTB) can inhibit its growth and metabolism, potentially enhancing the efficacy of existing TB treatments...
- This federal Project Grant award of $895,538 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant will fund research to discover all-oral sterilizing drug regimens, either made of FDA-approved agents or integrating novel preclinical and clinical candidates, to shorten treatment duration for patients with Mycobacterium abscessus pulmonary disease (MAB-PD). The research aims to identify...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $750,000 Project Grant to The University of Southern Mississippi to research the role of extracellular polyphosphate in Mycobacterium tuberculosis antibiotic tolerance. The 4-year grant, which begins on Sep 20, 2025 and runs through Aug 31, 2029, aims to investigate the metabolic pathways in M. tuberculosis that regulate extracellular...